Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Cytek Biosciences Inc.

    NASDAQ: CTKB · Real-Time Price · USD
    3.23
    -0.13 (-3.87%)
    At close: Jun 13, 2025, 3:59 PM
    3.22
    -0.31%
    After-hours: Jun 13, 2025, 04:36 PM EDT

    Cytek Biosciences Statistics

    Share Statistics

    Cytek Biosciences has 126.66M shares outstanding. The number of shares has increased by -2.42% in one year.

    Shares Outstanding

    n/a
    		 126.66M

    Shares Change (YoY)

    n/a
    		 -2.42%

    Shares Change (QoQ)

    n/a
    		 -0.55%

    Owned by Institutions (%)

    n/a
    		 58.98%

    Shares Floating

    n/a
    		 114.67M

    Failed to Deliver (FTD) Shares

    n/a
    		 44

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 5.41M, so 4.27% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 5.41M

    Short % of Shares Out

    n/a
    		 4.27%

    Short % of Float

    n/a
    		 5.56%

    Short Ratio (days to cover)

    n/a
    		 4.64

    Valuation Ratios

    The PE ratio is -140.81 and the forward PE ratio is -48.07. Cytek Biosciences's PEG ratio is 2.89.

    PE Ratio

    n/a
    		 -140.81

    Forward PE

    n/a
    		 -48.07

    PS Ratio

    n/a
    		 4.23

    Forward PS

    n/a
    		 1.3

    PB Ratio

    n/a
    		 2.14

    P/FCF Ratio

    n/a
    		 38.79

    PEG Ratio

    n/a
    		 2.89
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Cytek Biosciences.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 5.86, with a Debt / Equity ratio of 0.04.

    Current Ratio

    n/a
    		 5.86

    Quick Ratio

    n/a
    		 5.21

    Debt / Equity

    n/a
    		 0.04

    Debt / EBITDA

    n/a
    		 -1.7

    Debt / FCF

    n/a
    		 0.78

    Interest Coverage

    n/a
    		 -3.92

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $302,342.38

    Profits Per Employee

    n/a
    		 $-9,079.94

    Employee Count

    n/a
    		 663

    Asset Turnover

    n/a
    		 0.4

    Inventory Turnover

    n/a
    		 2.04

    Taxes

    Income Tax

    n/a
    		 320K

    Effective Tax Rate

    n/a
    		 -5.61%

    Stock Price Statistics

    The stock price has increased by -42.53% in the last 52 weeks. The beta is 1.26, so Cytek Biosciences's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.26

    52-Week Price Change

    n/a
    		 -42.53%

    50-Day Moving Average

    n/a
    		 3.32

    200-Day Moving Average

    n/a
    		 4.97

    Relative Strength Index (RSI)

    n/a
    		 51.28

    Average Volume (20 Days)

    n/a
    		 1,070,215

    Income Statement

    In the last 12 months, Cytek Biosciences had revenue of 200.45M and earned -6.02M in profits. Earnings per share was -0.05.

    Revenue

    n/a
    		 200.45M

    Gross Profit

    n/a
    		 111.11M

    Operating Income

    n/a
    		 -20.52M

    Net Income

    n/a
    		 -6.02M

    EBITDA

    n/a
    		 -10.03M

    EBIT

    n/a
    		 -20.52M

    Earnings Per Share (EPS)

    n/a
    		 -0.05
    Full Income Statement

    Balance Sheet

    The company has 98.72M in cash and 17.02M in debt, giving a net cash position of 81.7M.

    Cash & Cash Equivalents

    n/a
    		 98.72M

    Total Debt

    n/a
    		 17.02M

    Net Cash

    n/a
    		 81.7M

    Retained Earnings

    n/a
    		 -35.2M

    Total Assets

    n/a
    		 482.6M

    Working Capital

    n/a
    		 312.81M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was 25.38M and capital expenditures -3.52M, giving a free cash flow of 21.85M.

    Operating Cash Flow

    n/a
    		 25.38M

    Capital Expenditures

    n/a
    		 -3.52M

    Free Cash Flow

    n/a
    		 21.85M

    FCF Per Share

    n/a
    		 0.17
    Full Cash Flow Statement

    Margins

    Gross margin is 55.43%, with operating and profit margins of -10.24% and -3%.

    Gross Margin

    n/a
    		 55.43%

    Operating Margin

    n/a
    		 -10.24%

    Pretax Margin

    n/a
    		 -2.84%

    Profit Margin

    n/a
    		 -3%

    EBITDA Margin

    n/a
    		 -5.01%

    EBIT Margin

    n/a
    		 -10.24%

    FCF Margin

    n/a
    		 10.9%

    Dividends & Yields

    CTKB does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for CTKB is $6.5, which is 101.2% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $6.5

    Price Target Difference

    n/a
    		 101.2%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 4
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 2.77

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist